Company intelligence / Profile preview

Blockbuster

Worcester, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Blockbuster Therapeutics was a Massachusetts-based biotechnology company focused on developing novel regenerative therapies for spinal cord injuries. The company's lead program, RMx, was designed as an alternative to embryonic stem cells for treating neural damage. Blockbuster Therapeutics also held licenses for technologies such as Trans-Neural Implants and SpheroGel, a hydrogel-based delivery system for neural stem cells. Despite early clinical ambitions in the mid-2000s, the company is no longer active in the life sciences sector.

Therapeutic areas: Neurology
Modalities: Cell therapyStem cell therapy
Industry: Biotech

Partnerships

NeuroVita

Beyond the preview

Go deeper on Blockbuster.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blockbuster.

Explore the full profile